Real-World Effectiveness of Risankizumab in Patients With Psoriatic Arthritis: 6-Month Interim Results From the Observational PErsistence With RISankizumab (PERIS) Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1326; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; P | "In this observational study, patients treated with RZB up to 6 months showed improvements in overall disease activity, as well as in joint, enthesitis, dactylitis, and skin domains, supporting the real-world effectiveness of RZB in PsA, consistent with existing clinical trial data."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A
|
|
Carlo Selmi 1; Georgios Vosvotekas 2; Nikolaos Kougkas 3; Philipe Goupille 4; Anastas Batalov 5; Jan Brandt-Juergens 6; Thomas Iyile 7; Xiao Li 8; Meng Zhang 7; Ralph Lippe 7; Tae Jin Park 7; and Fabian Proft 9
|